Cellectis

Cellectis S.A. ADR
Stock Exchange Frankfurt Stock Exchange
EPS
EUR1.4
Market Cap
EUR585.75 M
Shares Outstanding
42.41 M
Public Float
-
Cellectis S.A.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
41.61 M
Public Float
-
Cellectis S.A. ADR
Stock Exchange NASDAQ Stock Market
EPS
$1.61
Market Cap
$686.77 M
Shares Outstanding
42.45 M
Public Float
41.86 M

Profile

Address
8, rue de la Croix Jarry
Paris Ile-de-France 75013
France
Employees -
Website http://www.cellectis.com
Updated 07/08/2019
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases.

Financials

View All
Created with Highcharts 5.0.14Cellectis S.A.Net Income. Fiscal year is January-December. All values EUR Thousands.25 82225 8222 8422 84220 54420 54460 77660 77688 09788 09766 70366 703201320142015201620172018020k40k60k80k100k
Created with Highcharts 5.0.14Cellectis S.A.Sales/Revenue. Fiscal year is January-December. All values EUR Thousands.5 3625 36221 62721 62750 34650 34640 49140 49122 33122 33110 79110 791201320142015201620172018010k20k30k40k50k60k

André Choulika
Chairman & Chief Executive Officer
David J. Sourdive
Director & EVP-Technical Operations